Cycling Weekly on MSN
The most surprising bike I rode in 2025: The Pinarello Grevil F3 reviewed
The Grevil G is a modern gravel bike that understands that long events still involve attacking, cornering and sprinting — and ...
Cycling News on MSN
SRAM officially launches Jonas Vingegaard's 150mm crank arms
SRAM claims shorter crank arms give riders better efficiency and more comfort. Red crank arms are now available in 150-175mm ...
SRAM’s XX SL Eagle AXS Transmission is the brand’s ultra-high-spec, lightweight cross-country racing groupset that’s also tough enough for enduro use. It sets the benchmark for long-term reliable ...
Hosted on MSN
Velo 2025 product of the year winner: SRAM Force AXS
SRAM Force AXS gets the nod as this year’s Velo Product of the year. Here’s how we got there. When our team worked on the Velo Best Products of 2025 nominations, the winner involved a fair bit of ...
Single chainrings on the road have until now been the preserve of a few small devotee brands. 3T started the ball rolling and ...
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Axsome Therapeutics (AXSM) is trading sharply higher after announcing this morning that the FDA accepted for filing its supplemental New Drug Application (sNDA) for AXS-05 in Alzheimer's disease (AD) ...
(RTTNews) - Axsome Therapeutics Inc. (AXSM) announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr ...
(MENAFN- GlobeNewsWire - Nasdaq) FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc.
AXIS Capital Holdings (AXS) has quietly rewarded patient shareholders, with the stock up about 21% this year and more than doubling over the past 3 years, outpacing many insurance peers. See our ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical ...
Sarah is an experienced writer and editor enthusiastic about helping readers live their healthiest and happiest lives. Before joining Forbes Health, Sarah worked as a writer for various digital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results